Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for strongest quarter in years as risk appetite holds despite US-Iran war
- Dollar pushes higher, yen sinks to 40-year low
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 94c
August 5, 2021 4:34 PM EDTVir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of $0.46, $0.94 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $177.07 million versus the consensus estimate of $84.56 million.
Vir made strong progress this quarter across our extensive infectious disease portfolio, the most notable of which is that our monoclonal antibody sotrovimab is now available for patients who become ill with COVID-19... More
